

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
PATENT EXAMINING OPERATION

First Named Inventor: Kevin J. WILLIAMS

Serial No: 10/525,610

Group Art Unit: 1643

Filed: March 24, 2006

Examiner: HARRIS A.M.

Att. Docket No.: W1107/20010

Confirmation No.: 7982

For: Thrombospondin Fragments and Uses Thereof in Clinical Assays for Cancer and  
Generation of Antibodies and Other Binding Agents

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**with CERTIFICATION STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INTRODUCTORY COMMENTS**

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-form 1449. It is respectfully requested that the information be considered during the prosecution of this application, and that the reference be made of record therein and appear among the "References Cited" on any patent to issue on the present application. No representation is made that any reference listed is prior art with respect to this application.

With 2 exceptions, the references cited were submitted in connection with an Information Disclosure Statement submitted on December 18, 2007, to the Patent Office in parent application Ser.No. 10/419,462, filed April 21, 2003, which is relied upon for an earlier filing date under 35 U.S.C. §120. Thus with those exceptions, copies of the references are not attached. 37 CFR

Application No. 10/525,610  
Supplemental IDS

§1.98(d). The 2 exceptions are Zhang *et al.*, Cite No. 21 and Wang-Rodriguez *et al.*, Cite No. 47.

The specified filing date of March 24, 2006 does not take into account that the present application represents a national phase application based on a PCT application filed August 20, 2003. Accordingly, Applicant understands that no prior art dated subsequent to August 20, 2003 need be submitted as part of any Information Disclosure Statement for this application.

The Cite Nos. of the references for the present IDS are the same as those on the December 18, 2007 IDS submitted in parent application Ser. No. 10/416,492, except that (1) Stancik *et al.*, was replaced by Zhang *et al* as Cite No. 21, and (2) Cite Nos. 47 is new. (Stancik *et al.* was previously submitted in the present case.)

Cite No. 28, Huang *et al.*, is a more legible copy of that publication than was previously submitted. It was previously submitted with the Information Disclosure Statement of October 24, 2006 as item DM.

Each nonpatent reference being submitted electronically herewith has its file name indicating the first author, year, and Form PTO-1449 Cite No.: For example, **Zhang\_2003\_CiteNo-21.**

Three of the Citations refer to NIH grant abstracts obtained from the NIH CRISP database and the date specified is that of the start date of the grant as the database does not specify the publication date of the abstract.

#### **Certification Statement referred to on Form PTO/SB/08a**

This Information Disclosure Statement is being filed before the mailing of a First Office

Application No. 10/525,610  
Supplemental IDS

Action on the merits. No certification or fee is required.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,  
COHEN & POKOTILOW, LTD.

December 26, 2007

Please charge or credit our  
Account No. 03-0075 as necessary  
to effect entry and/or ensure  
consideration of this submission.

By Allan H. Fried

Allan H. Fried

Registration No. 31,253

Customer No. 03000

(215) 567-2010

Attorneys for Applicants